Whalesbook
THE SEAMLESS LINK
This high-stakes legal determination is poised to bring much-needed clarity to the intersection of intellectual property and antitrust enforcement in India, with significant implications for innovation-driven industries and their market conduct.
The Jurisdictional Crossroads
The Supreme Court's intervention signals a pivotal moment for India's regulatory framework. A bench has indicated it will decide the jurisdictional boundaries between the Competition Act, 2002, and the Patents Act, 1970. This follows previous rulings, including a significant National Company Law Appellate Tribunal (NCLAT) judgment that had largely excluded patent-related disputes from the CCI's purview. The NCLAT's stance, which held that the Patents Act is a special statute that exclusively governs such issues, has been put on hold by the apex court as it prepares to deliver its verdict on jurisdiction alone. The current appeal before the Supreme Court directly challenges this jurisdictional pronouncement by the NCLAT.
Precedent and the Patents Act Dominance
The NCLAT's reasoning often relied on a 2023 Delhi High Court division bench decision in the Ericsson–Monsanto cases. This precedent established that the Patents Act is a comprehensive code, precluding the CCI from investigating allegations of abuse of dominance stemming from patent rights. The high court reasoned that such matters fall within the exclusive domain of patent law. The Supreme Court had previously declined to interfere with this Delhi High Court ruling, leaving broader legal questions open, which the NCLAT subsequently applied. Cases involving pharmaceutical firms like Vifor International AG, whose patented drug Ferric Carboxymaltose (FCM) was subject to a complaint, have been instrumental in bringing this jurisdictional conflict to the forefront, with NCLAT affirming the Patents Act's precedence. The NCLAT's decision in the Vifor International AG case, for instance, closed a complaint by holding that the CCI lacked jurisdiction, emphasizing that the Patents Act prevails.
Sectoral Ramifications
The pharmaceutical sector, in particular, watches this development closely. Companies invest heavily in research and development, relying on patent protection to recoup costs and incentivize further innovation. A clear jurisdictional line between patent law and competition law is essential for predictable market operations. Uncertainty can stifle investment and lead to protracted legal battles. This ruling will influence how pharmaceutical companies, as well as other technology and IP-intensive industries, manage their patent portfolios and market strategies within India. The interplay between these laws has been a persistent challenge, as patent holders may sometimes be accused of leveraging their exclusive rights in ways that raise competition concerns.
Market Watch
CSL Limited, the parent company of Vifor International AG, reported a Price-to-Earnings (P/E) ratio of approximately 20.47 as of January 2026, with its stock trading around AUD 181.42 on January 30, 2026. The company's recent performance indicates low single-digit revenue growth expectations for fiscal year 2026, with plans to demerge its Seqirus vaccine business. Meanwhile, Telefonaktiebolaget LM Ericsson (Ericsson) has seen its stock trading around $11.12 USD on January 27, 2026, with a P/E ratio hovering between 12 to 14.7 in late 2025 and early 2026. Recent news for Ericsson includes plans for significant job cuts and advancements in private 5G network deployments. The market will be closely monitoring how the Supreme Court's decision on CCI's jurisdiction impacts the strategic and operational landscapes for these entities and their peers.